Roche ramps up obesity-drug competition with early-stage trial results
By Eleanor Laise
Experimental injection's efficacy looks on par with popular drugs from Eli Lilly, Novo Nordisk, analysts say
The race to develop powerful new weight-loss drugs grew even more heated on Thursday as Roche Holding AG released early-stage trial results for an experimental obesity treatment.
The once-weekly injection, known as CT-388, produced average weight loss of 18.8% after six months, the Swiss drugmaker said in a release. All patients treated with the drug lost more than 5% of their body weight, the company said, and nearly half lost more than 20%.
The "weight loss results are encouraging," making the Roche drug's efficacy look competitive with treatments already on the market, such as Novo Nordisk's (NVO) Wegovy, as well as other experimental drugs in the pipeline, Jefferies analysts said in a note Thursday. But "there is still a long road ahead," the analysts said, and more data is needed to put the results in context.
Similar to Eli Lilly & Co.'s Zepbound, which received U.S. regulatory approval for treating obesity late last year, Roche's experimental treatment acts on two gut hormones, GLP-1 and GIP.
Roche is developing CT-388 for the treatment of Type 2 diabetes, as well as obesity. In a subgroup of trial participants with pre-diabetes, the drug normalized blood sugar in all patients, the company said.
Some patients had mild to moderate gastrointestinal side effects, Roche said - an issue common among this new class of weight-loss drugs.
More data from the ongoing phase 1 trial of CT-388, focused on patients with obesity and type 2 diabetes, are expected in the second half of this year, Roche said.
Roche's American depositary receipts (RHHBY) gained 3.5% premarket Thursday and have dropped 13.3% in the year to date.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-16-24 0841ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now